Voyager Therapeutics Announces Promising Early-Stage Results for Gene Therapy Aimed at Attenuating Tau in Alzheimer's, Pushes Project into Later Research Phase.
Hospitalization data for darolutamide/docetaxel in metastatic prostate cancer were presented at 2024 ASCO_GU on Jan 25, comparing daro/docetaxel/ADT with placebo/docetaxel/ADT.
Immune-Onc Therapeutics Discloses a Partnership for Clinical Research, Assessing IO-108 in an International Early Phase Trial Aimed at Initial Therapy for Progressive Hepatic Carcinoma.
On January 30, 2024, Regeneron revealed plans to acquire 2seventy bio's immuno-cell therapy pipeline and related manufacturing capabilities under a new agreement.
The FDA has granted Mabwell authorization to proceed with their new ADC targeting B7-H3, referred to as 7MW3711 under an Investigational New Drug application.
Iterion Therapeutics stated that initial dosing has commenced in an early to mid-stage study of their drug Tegavivint for advanced liver cancer cases unresponsive to previous systemic therapies.